

Amendments

In the Claims

Please amend the claims as indicated below. This version of the claims will replace all prior versions.

1. (currently amended) A method for inhibiting tumor growth in a mammal comprising the steps of administering to the mammal:

an anti-endoglin antibody SN6j or antigen binding fragment thereof; and

a chemotherapeutic agent selected from the group consisting of
cyclophosphamide (CPA) or doxorubicin,

wherein the combination of the anti-endoglin antibody SN6j or antigen binding fragment thereof and the chemotherapeutic agent has a synergistic effect on the inhibition of tumor growth.

2.-4. (canceled)

5. (original) The method of claim 1, wherein the antigen binding fragment is selected from the group consisting of F(ab')₂, Fab', Fab, Fv, Fd', Fd, single chain Fv and derivatives of single chain Fv fragments.

6. (currently amended) The method of claim 1, wherein the anti-endoglin antibody SN6j and the chemotherapeutic agent are administered sequentially.

7. (currently amended) The method of claim 1, wherein the anti-endoglin antibody SN6j and the chemotherapeutic agent are administered simultaneously.

8. (canceled)

9. (currently amended) The method of claim 1, wherein the ~~anti-endoglin antibody is SN6j~~ and the chemotherapeutic agent is cyclophosphamide.
10. (currently amended) The method of claim 1, wherein the ~~anti-endoglin antibody is SN6j~~ and the chemotherapeutic agent is doxorubicin.
11. (original) A method for inhibiting tumor growth in a mammal comprising the steps of administering to the mammal:
 - an anti-endoglin antibody which binds to the same epitope as SN6j or an antigen binding fragment of the anti-endoglin antibody; and
 - a chemotherapeutic agent selected from the group consisting of cyclophosphamide and doxorubicinwherein the combination of the anti-endoglin antibody or antigen binding fragment thereof and the chemotherapeutic agent has a synergistic effect on the inhibition of tumor growth.
12. (original) The method of claim 11 wherein the chemotherapeutic agent is cyclophosphamide.
13. (original) The method of claim 11 wherein the chemotherapeutic agent is doxorubicin.